US Tech Giants’ AI Bond Boom Raises Euro Zone Borrowing Risks 
Fast Retailing Shares Drop as Uniqlo Japan August Sales Fall 
Audi, SAIC Launch China Innovation Hub for New AUDI Models 
Tesla Cybercab Launch Puts Robotaxi Ambitions in Focus 
Lynas Rare Earths Shares Rise After Takeover Talks Revealed 
South Korea, US Discuss Chip Investments Amid Tariff Plans 
Lenovo Shares Fall After Dropbox Security Breach Exposes ID Vulnerability 
OpenAI Rejects Apple Trade Secret Theft Claims 
Qantas Near-Miss Raises Sydney Air Traffic Controller Fatigue Concerns 
Shein Shares Drop 5% After Weak Hong Kong IPO Debut 
MongoDB Stock Sinks 14% as Atlas Growth Misses Expectations 
Microsoft to Reveal Azure Revenue in Major Reporting Shake-Up 
Volkswagen Approves 50,000 More Job Cuts in Major Restructuring 
Milei Threatens Falkland Oil Firms With Sanctions 
Nvidia Eyes $2.5 Billion Investment in Thinking Machines Lab 
France Targets Shein, Temu With Fast-Fashion Fees 
CATL Shares Fall as Hungary Plant Faces Safety Halt 
Add as a preferred source on Google
LOS ANGELES, March 05, 2018 -- Ritter Pharmaceuticals, Inc. (NASDAQ:RTTR) (“Ritter Pharmaceuticals” or the “Company”), a developer of novel therapeutics that modulate the gut microbiome to treat gastrointestinal diseases with an initial focus on establishing the first FDA-approved treatment for lactose intolerance, today announced that the Company will present at the 30th Annual ROTH Conference on March 13, 2018, at 8:00 a.m. PT in Dana Point, California.
Ritter Pharmaceuticals’ management team will also be available to participate in one-on-one meetings with investors on March 12-13. Conference participants who are interested in scheduling a meeting should Email [email protected].
The conference will be held March 11-14, 2018, at the Ritz Carlton in Dana Point, California.
The Company’s presentation will be available for the public to access at www.ritterpharma.com.
About Ritter Pharmaceuticals
Ritter Pharmaceuticals, Inc. (www.RitterPharma.com, @RitterPharma) develops novel therapeutic products that modulate the gut microbiome to treat gastrointestinal diseases. The Company’s lead product, RP‐G28, has the potential to become the first FDA‐approved treatment for lactose intolerance, a condition that affects millions worldwide. RP-G28 has been studied in Phase 2 trials and is now in Phase 3 clinical development. The Company is further exploring the functionality and discovering the therapeutic potential gut microbiome changes may have on treating/preventing a variety of conditions including: gastrointestinal diseases, immuno‐oncology, metabolic, and liver disease.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements refer to future plans and expectations, including statements regarding the timing of our first Phase 3 pivotal clinical trial. Management believes that these forward-looking statements are reasonable as and when made. However, such statements involve a number of known and unknown risks and uncertainties that could cause the Company’s future results, performance or achievements to differ significantly from the results, performance or achievements expressed or implied by such forward-looking statements. Factors that could affect the Company’s actual results are included in the Company’s SEC filings, including the Company’s most recent reports on Form 10-K and 10-Q filed with the SEC. These forward-looking statements are made only as of the date hereof, and, except as required by law, the Company undertakes no obligation to update or revise its forward-looking statements, whether as a result of new information, future events or otherwise.
Contacts
Investor Contact:
Jeffrey Benjamin
310-203-1000
[email protected]
